Literature DB >> 25136021

In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.

Aspasia Katragkou1, Matthew McCarthy1, Joseph Meletiadis2, Vidmantas Petraitis1, Patriss W Moradi1, Gittel E Strauss1, Monique M Fouant3, Laura L Kovanda3, Ruta Petraitiene1, Emmanuel Roilides4, Thomas J Walsh5.   

Abstract

Whether isavuconazole, an extended-spectrum triazole, possesses synergistic activity in combination therapy with echinocandins or amphotericin B for the treatment of invasive molds infections has not been studied. Our in vitro combination studies showed that isavuconazole and micafungin are synergistically active against Aspergillus fumigatus, Aspergillus flavus, Aspergillus terreus, and Cunninghamella bertholletiae. These results suggest that isavuconazole, in combination with micafungin, may have a role in the treatment of invasive aspergillosis and warrants further investigation.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25136021      PMCID： PMC4249375          DOI： 10.1128/AAC.03261-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Alia A Sarafandi; Amy M Kelaher; Caron A Lyman; Heather E Casler; Tin Sein; Andreas H Groll; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  J Infect Dis       Date:  2003-06-04       Impact factor: 5.226

2.  The problem of synergism and antagonism of combined drugs.

Authors:  S LOEWE
Journal:  Arzneimittelforschung       Date:  1953-06

3.  Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro.

Authors:  G L Drusano; D Z D'Argenio; W Symonds; P A Bilello; J McDowell; B Sadler; A Bye; J A Bilello
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.

Authors:  Livio Pagano; Morena Caira; Anna Candoni; Massimo Offidani; Luana Fianchi; Bruno Martino; Domenico Pastore; Marco Picardi; Alessandro Bonini; Anna Chierichini; Rosa Fanci; Cecilia Caramatti; Rosangela Invernizzi; Daniele Mattei; Maria Enza Mitra; Lorella Melillo; Franco Aversa; Maria Teresa Van Lint; Paolo Falcucci; Caterina Giovanna Valentini; Corrado Girmenia; Annamaria Nosari
Journal:  Haematologica       Date:  2006-08       Impact factor: 9.941

5.  Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models.

Authors:  Joseph Meletiadis; Paul E Verweij; Debbie T A TeDorsthorst; Jacques F G M Meis; Johan W Mouton
Journal:  Med Mycol       Date:  2005-03       Impact factor: 4.076

6.  Colorimetric assay for antifungal susceptibility testing of Aspergillus species.

Authors:  J Meletiadis; J W Mouton; J F Meis; B A Bouman; J P Donnelly; P E Verweij
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

7.  In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.

Authors:  Michael A Pfaller; Shawn A Messer; Paul R Rhomberg; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-06-05       Impact factor: 5.948

8.  In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates.

Authors:  Joseph Meletiadis; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach.

Authors:  D T A Te Dorsthorst; P E Verweij; J Meletiadis; M Bergervoet; N C Punt; J F G M Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

10.  Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Markus Heep; Michael Schleimer; Erhard Weidekamm; Tom Brown; Michael Roehrle; Christoph Beglinger
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938
View more
  11 in total

1.  Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Matthew W McCarthy; Laura L Kovanda; Myo H Zaw; Kaiser Hussain; Naima Shaikh; Bo Bo W Maung; Navjot K Sekhon; William W Hope; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  In Vitro Combination of Isavuconazole with Echinocandins against Azole-Susceptible and -Resistant Aspergillus spp.

Authors:  A Raffetin; V Courbin; V Jullien; E Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 3.  Aspergillus fumigatus and Aspergillosis in 2019.

Authors:  Jean-Paul Latgé; Georgios Chamilos
Journal:  Clin Microbiol Rev       Date:  2019-11-13       Impact factor: 26.132

4.  Natamycin and Voriconazole Exhibit Synergistic Interactions with Nonantifungal Ophthalmic Agents against Fusarium Species Ocular Isolates.

Authors:  Michael E Zegans; Robert A Cramer; Christiaan A Rees; Ruina Bao
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

Review 5.  Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.

Authors:  Alice J Hsu; Pranita D Tamma; Brian T Fisher
Journal:  Antimicrob Agents Chemother       Date:  2022-06-29       Impact factor: 5.938

6.  Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Aspasia Katragkou; Bo Bo Win Maung; Ethan Naing; Povilas Kavaliauskas; Stephen Barat; Katyna Borroto-Esoda; Nkechi Azie; David Angulo; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

Review 7.  Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations.

Authors:  Suganthini Krishnan Natesan; Pranatharthi H Chandrasekar
Journal:  Infect Drug Resist       Date:  2016-12-07       Impact factor: 4.003

8.  Emergence of Echinocandin Resistance Due to a Point Mutation in the fks1 Gene of Aspergillus fumigatus in a Patient with Chronic Pulmonary Aspergillosis.

Authors:  Cristina Jiménez-Ortigosa; Caroline Moore; David W Denning; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

Review 9.  Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis.

Authors:  Liliana Scorzoni; Ana C A de Paula E Silva; Caroline M Marcos; Patrícia A Assato; Wanessa C M A de Melo; Haroldo C de Oliveira; Caroline B Costa-Orlandi; Maria J S Mendes-Giannini; Ana M Fusco-Almeida
Journal:  Front Microbiol       Date:  2017-01-23       Impact factor: 5.640

10.  In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates.

Authors:  J B Buil; R J M Brüggemann; L Bedin Denardi; W J G Melchers; P E Verweij
Journal:  J Antimicrob Chemother       Date:  2020-09-01       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.